The Case for Proteomics and Phospho-Proteomics in Personalized Cancer Medicine

Proteomics. Clinical Applications
Sophia DollMatthias Mann

Abstract

The concept of personalized medicine is predominantly been pursued through genomic and transcriptomic technologies, leading to the identification of multiple mutations in a large variety of cancers. However, it has proven challenging to distinguish driver and passenger mutations and to deal with tumor heterogeneity and resistant clonal populations. More generally, these heterogeneous mutation patterns do not in themselves predict the tumor phenotype. Analysis of the expressed proteins in a tumor and their modification states reveals if and how these mutations are translated to the functional level. It is already known that proteomic changes including posttranslational modifications are crucial drivers of oncogenesis, but proteomics technology has only recently become comparable in depth and accuracy to RNAseq. These advances also allow the rapid and highly sensitive analysis of formalin-fixed and paraffin-embedded biobank tissues, on both the proteome and phosphoproteome levels. In this perspective, pioneering mass spectrometry-based proteomic studies are highlighted that pave the way toward clinical implementation. It is argued that proteomics and phosphoproteomics could provide the missing link to make omics analysis actionab...Continue Reading

References

Jul 21, 2001·Health Affairs·C HoganJ Lynn
Jan 9, 2009·Journal of Proteome Research·Brian M BalgleyCheng S Lee
Apr 16, 2010·Nature·UNKNOWN International Cancer Genome ConsortiumHuanming Yang
Aug 27, 2010·Science Translational Medicine·Harald MischakAntonia Vlahou
Dec 31, 2010·Nature Reviews. Genetics·Fatih Ozsolak, Patrice M Milos
Nov 10, 2011·Molecular Systems Biology·Nagarjuna NagarajMatthias Mann
Jan 10, 2012·Current Opinion in Chemical Biology·A F Maarten Altelaar, Albert J R Heck
Jul 24, 2012·Cell·Eran HodisLynda Chin
Aug 7, 2012·Molecular & Cellular Proteomics : MCP·Amelia C PetersonJoshua J Coon
Aug 21, 2012·Nucleic Acids Research·Abel Gonzalez-Perez, Nuria Lopez-Bigas
Sep 13, 2012·Molecular Systems Biology·Jacek R WiśniewskiMatthias Mann
Nov 15, 2012·Clinical Chemistry·N Leigh AndersonNader Rifai
Feb 27, 2013·Molecular Cell·Matthias MannJürgen Cox
May 3, 2013·Nature·Cyriac KandothDouglas A Levine
Jun 25, 2013·Nature·UNKNOWN Cancer Genome Atlas Research Network
Sep 21, 2013·Nature·Rebecca A BurrellCharles Swanton
Sep 21, 2013·Nature Protocols·Namrata D UdeshiSteven A Carr
Nov 6, 2013·Molecular & Cellular Proteomics : MCP·Sally J DeebMatthias Mann
Jan 31, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Feb 14, 2014·Nature Methods·James EberwineJunhyong Kim
Jul 22, 2014·Nature·Bing ZhangUNKNOWN NCI CPTAC
Jul 24, 2014·Nature Reviews. Molecular Cell Biology·Chunaram ChoudharyMatthias Mann
Aug 1, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Oct 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joyce Liu, Ursula A Matulonis
Nov 28, 2014·Nature·Matthew M GubinRobert D Schreiber
Dec 18, 2014·Nucleic Acids Research·Peter V HornbeckElzbieta Skrzypek
Dec 30, 2014·ACS Chemical Biology·Sophia Doll, Alma L Burlingame

❮ Previous
Next ❯

Citations

Feb 16, 2019·Proteomics. Clinical Applications·Maria FrantziAgnieszka Latosinska
May 20, 2020·Expert Review of Proteomics·Alain Van GoolMarei Sammar
Feb 11, 2020·Frontiers in Cell and Developmental Biology·Joseph Parsons, Chiara Francavilla
Jun 4, 2020·Clinical Proteomics·Andrew MacklinThomas Kislinger
Aug 2, 2020·Nature Protocols·Katarzyna BuczakAlessandro Ori
Jul 28, 2020·Nature Reviews. Genetics·Christopher Buccitelli, Matthias Selbach
Apr 28, 2020·BioMed Research International·Juan Ramón Padilla-MendozaIsrael López-Reyes
Mar 11, 2020·The Journal of Pathology·Fabian CosciaMatthias Mann
Aug 15, 2020·Neuro-oncology Advances·Lennard J M DekkerTheo M Luider
Dec 16, 2020·Biochimica Et Biophysica Acta. Proteins and Proteomics·Jiajia Li, Xianquan Zhan
Jan 22, 2021·Seminars in Cancer Biology·Natalie Jäger
Dec 17, 2020·Journal of Personalized Medicine·Ioana-Ecaterina PraleaCristina-Adela Iuga
Jan 8, 2021·Tissue Engineering. Part C, Methods·Vera M PietersAlison P McGuigan
May 4, 2020·Journal of Proteomics·Elisabetta Boeri ErbaCarlo Petosa
Mar 27, 2021·Expert Review of Precision Medicine and Drug Development·Michael H RoehrlJulia Y Wang
Mar 22, 2021·Cardiovascular Research·Sina SafabakhshZachary Laksman
Sep 9, 2020·Analytical Chemistry·Shay VimerMichal Sharon
Dec 23, 2020·Journal of Proteome Research·Jinming ZhangNing Liu
Sep 3, 2021·Briefings in Bioinformatics·Mohammad Reza KarimiUlf Schmitz
Nov 24, 2021·Journal of the American Society for Mass Spectrometry·James A SanfordPaul D Piehowski

❮ Previous
Next ❯

Methods Mentioned

BETA
exome sequencing
GTPase
RNAseq
biopsies
affinity purification
laser capture microdissection
acetylation
xenograft

Software Mentioned

PhosphoSitePlus
BoxCar

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

© 2022 Meta ULC. All rights reserved